Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

被引：12
|
作者：
Ryan, P. D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Neven, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Blackwell, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Dirix, L. Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Barrios, C. H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Miller, W. H., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fein, L. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fenton, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Benner, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Meech, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Paccagnella, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Sleight, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Yee, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Goss, P. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Ziekenhuis Leuven, Leuven, Belgium
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Sint Augustinus, Oncol Ctr, Antwerp, Belgium
[5] PUCRS Sch Med, Porto Alegre, RS, Brazil
[6] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[7] Ctr Oncol Rosario, Santa Fe, Argentina
[8] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[9] Pfizer Inc, Groton, CT 06340 USA
[10] Univ Minnesota, Minneapolis, MN USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer
    Kwa, Maryann
    Li, Xiaochun
    Novik, Yelena
    Oratz, Ruth
    Jhaveri, Komal
    Wu, Jennifer
    Gu, Ping
    Meyers, Marleen
    Muggia, Franco
    Speyer, James
    Iwano, Alyssa
    Bonakdar, Maryam
    Kozhaya, Lina
    Tavukcuoglu, Ece
    Budan, Bahar
    Raad, Roy
    Goldberg, Judith D.
    Unutmaz, Derya
    Adams, Sylvia
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 57 - 67
  • [22] Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer
    Maryann Kwa
    Xiaochun Li
    Yelena Novik
    Ruth Oratz
    Komal Jhaveri
    Jennifer Wu
    Ping Gu
    Marleen Meyers
    Franco Muggia
    James Speyer
    Alyssa Iwano
    Maryam Bonakdar
    Lina Kozhaya
    Ece Tavukcuoglu
    Bahar Budan
    Roy Raad
    Judith D. Goldberg
    Derya Unutmaz
    Sylvia Adams
    Breast Cancer Research and Treatment, 2018, 168 : 57 - 67
  • [23] Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer
    Esteva, Francisco J.
    Moulder, Stacy L.
    Gonzalez-Angulo, Ana M.
    Ensor, Joe
    Murray, James L.
    Green, Marjorie C.
    Koenig, Kimberly B.
    Lee, Mong-Hong
    Hortobagyi, Gabriel N.
    Yeung, Sai-Ching
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 63 - 72
  • [24] A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
    Hope S. Rugo
    Olivier Trédan
    Jungsil Ro
    Serafin M. Morales
    Mario Campone
    Antonino Musolino
    Noémia Afonso
    Marta Ferreira
    Kyong Hwa Park
    Javier Cortes
    Antoinette R. Tan
    Joanne L. Blum
    Lamar Eaton
    Christine K. Gause
    Zhen Wang
    Ellie Im
    David J. Mauro
    Mary Beth Jones
    Andrew Denker
    José Baselga
    Breast Cancer Research and Treatment, 2017, 165 : 601 - 609
  • [25] A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
    Rugo, Hope S.
    Tredan, Olivier
    Ro, Jungsil
    Morales, Serafin M.
    Campone, Mario
    Musolino, Antonino
    Afonso, Noemia
    Ferreira, Marta
    Park, Kyong Hwa
    Cortes, Javier
    Tan, Antoinette R.
    Blum, Joanne L.
    Eaton, Lamar
    Gause, Christine K.
    Wang, Zhen
    Im, Ellie
    Mauro, David J.
    Jones, Mary Beth
    Denker, Andrew
    Baselga, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 601 - 609
  • [26] Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
    de la Haba-Rodriguez, Juan
    Gonzalez Mancha, Rosario
    Perez Manga, Gumersindo
    Aranda Aguilar, Enrique
    Baena Canada, Jose Manuel
    Sanchez Rovira, Pedro
    Alba Conejo, Emilio
    CLINICAL BREAST CANCER, 2010, 10 (04) : 313 - 317
  • [27] THERAPEUTIC AND ECONOMIC VALUE OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2/NEU NEGATIVE ADVANCED BREAST CANCER
    Felix, J.
    Almeida, J.
    Ferreira, D.
    Rabiais, S.
    Vandewalle, B.
    VALUE IN HEALTH, 2015, 18 (07) : A453 - A453
  • [28] Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer Final Results from the Spanish Breast Cancer Group 2001-03 Phase 2 Randomized Trial
    Llombart-Cussac, Antonio
    Ruiz, Amparo
    Anton, Antonio
    Barnadas, Agusti
    Antolin, Silvia
    Ales-Martinez, Jose E.
    Alvarez, Isabel
    Andres, Raquel
    Garcia Saenz, Jose A.
    Lao, Juan
    Carrasco, Eva
    Camara, Carmen
    Casas, Isabel
    Martin, Miguel
    CANCER, 2012, 118 (01) : 241 - 247
  • [29] Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Schaaf, Larry
    Li, Xiaobai
    Ottman, Susan
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 151 - 156
  • [30] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
12345